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Background: Chronic lung infections and their treatment pose risks for the development of 
antimicrobial resistance (AMR) in people with cystic fibrosis (PWCF). In this study, we evaluated 
the attitudes of healthcare providers’ (HCP) and PWCF or their parents’ toward AMR within the 
international CF community. 
Methods: HCP and PWCF identified through listservs and CF-related organizations were asked 
to complete an AMR centered survey, with additional questions on antimicrobial stewardship 
(AMS) for HCP.  Descriptive analyses are reported. 
Results: The responding 443 HCP and 464 PWCF/Parents were from 30 and 25 countries, 
respectively. Sixty-two percent of HCP and 56% of PWCF stated they were “very concerned” 
about AMR, with Pseudomonas spp. and Burkholderia spp. considered the most concerning 
organisms for both HCP and PWCF/Parents. Non-tuberculous mycobacteria were of greater 
concern to HCP compared to PWCF/Parents. There was a discrepancy regarding AMR 
education to PWCF, with 80% of HCP stating having discussed this with PWCF/Parents, but 
only 50% of PWCF recalling such discussions. 
Conclusion: These results highlight that AMR is relevant to CF HCP and PWCF internationally, 




Antimicrobial resistance (AMR) broadly defined, refers to the inability of antimicrobials to 
effectively inhibit the growth of or kill a given microorganism.1 AMR is increasing among microbial 
opportunists, which is a major concern for healthcare providers (HCP), patients, and the general 
public. In CF, the emergence of AMR is multi-factorial due to chronic lung infections with bacterial 
adaptation and to the use of chronic suppressive antibiotic therapy with additional antibiotics for 
exacerbations.2,3,4,5  In CF care centers in the USA, proportions of people with CF (PWCF) with 
multi-drug resistant (MDR) Pseudomonas aeruginosa isolated from respiratory cultures has 
increased over time and is now 25-30%.5 Yet, greater use of antibiotics has been historically 
associated with better patient outcomes in CF, making the concept of using less antibiotics to 
decrease AMR challenging and situation dependent.
6,7,8
   
The increasing prevalence of AMR may require re-addressing antibiotic use more carefully in 
CF.9 Measures to address AMR have led to the development of hospital and community 
antimicrobial stewardship programs (AMS) around the world.
10,11 
The goals of AMS programs are 
to improve the treatment of infections by assisting in selection of antimicrobials, prescribing 
proper doses and durations, and monitoring for toxicity and other adverse effects.12  
The AMR in CF International Working Group (funded by European CF Society, U.S. CF 
Foundation, CF Trust, CF Australia, and CF Canada) was created to inform the CF community 
on important issues related to AMR.
2,13
 In order to design educational and/or treatment related 
interventions, it is important to understand current knowledge and attitudes of the stakeholders 
regarding AMR. The aim of this study was to assess the current knowledge, concerns, and 
educational needs of the CF community (i.e. PWCF or their parents, termed here 
PWCF/Parents) and HCP with regards to AMR. Further, we surveyed HCP about AMS resources 




A subgroup of the International Working Group developed a survey to explore five topics: 1) 
knowledge of AMR; 2) level of concern and perceived risks; 3) perceived consequences of 
AMR; 4) desired information; 5) preferred information sources. HCP were asked an additional 
six questions related to AMS.  The initial survey was pilot tested by ten internationally recruited 
HCP and eight PWCF from three CF centers. After modifications based on feed-back from pilot 
testers, the surveys (Survey Monkey) were distributed internationally to HCP and 
PWCF/Parents in July 2018 through the Cystic Fibrosis Foundation, the European Cystic 
Fibrosis Society, CF Canada, and CF Australia and were open for one month. Details of 
distribution and the complete survey are available in an online Supplement. Percentages were 
calculated as proportion of valid answers to each question. Data for sub-groups of 
PWCF/Parents are shown when relevant differences were noted. Descriptive statistics were 
performed using MS Excel and JMP®Pro 12.0.1 (SAS Institute). 
RESULTS 
We received responses from HCP (n=443) with various clinical roles from 30 countries, including 
78% where English was the respondent’s first language (Figure 1A). Providers were involved in 
pediatric care (44%), adult care (33%), or both age groups (23%). Among physicians, the majority 
(71%) were respirologists/pulmonologists, 5% were in infectious disease/infection control-
epidemiology, and 17% were classified as “other,” which included 11 general practitioners. Time 
engaged in the care of PWCF ranged from < 1 year to > 20 years (most common, 1-5 years 
(28%)) with an even distribution across the continuum. CF center sizes were evenly distributed in 
size, with numbers of PWCF ranging in four categories from <50 to >200; the majority reported 
being in centers with a size of 101-200 PWCF.  Among the PWCF/Parents (n=464) who 
responded, 25 countries were represented and 56% lived in an English-speaking country. The 
majority were parents of children with CF (Figure 1B). Response rates for survey completion was 
significantly higher for HCP than PWCF/Parents (mean ± SEM. 89.8 ± 0.02% vs. 73.4 ± 0.02%, 
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p<0.001). Response rates did not differ across topics in either group of respondents. 
Knowledge of AMR 
The term antibiotic and/or antimicrobial resistance was known to all but one social worker in the 
HCP group (~100%) and to 96% of PWCF/Parents. Using four vignettes and allowing more 
than one response, 88% of HCP and 66% of PWCF/Parents selected microbiology-laboratory 
based definitions of AMR and 61% of HCP and 81% of PWCF/Parents chose vignettes that 
indicated patient response to therapy as a clinical definition. Respondents were also asked for 
short descriptors of the term “antimicrobial resistance”. Descriptor responses (more than one 
answer allowed) were categorized into the following areas: 1) bacterial mechanisms, chosen by 
66% HCP and 57% PWCF/Families, with an additional 15% of HCP adding specific 
microbiology laboratory definitions 2) antibiotic/clinical outcomes-related definitions provided by 
4% and 14% of HCP and PWCF/Parents, respectively, and 3) definitions that implicated AMR 
as a host-related event were given by 1% of HCP and 9% of PWCF/Parents.  Nine percent of 
HCP and 5% of PWCF/Parents provided incomplete responses. Further, 7% of PWCF/Parents 
were unable to provide their own definition; these rates did not differ by primary language. 
Level of concern and perceived risks 
A majority of HCP (62%) and PWCF/Parents (56%) rated their concern about AMR as “very 
concerned”. In contrast, a single HCP and 1% of PWCF/Parents stated not being concerned 
about AMR. The estimated frequency of AMR in PWCF ranged from “some of the time” (48% 
HCW and 53% PWCF/Parents) to “most of the time” (42% HCW and 38% PWCF/Parents) to “all 
of the time” (9% in each group). 
A majority of respondents in each group perceived AMR risk to be different in some individuals 
with CF compared to others. Table 1 summarizes which situations (more than one answer 
allowed) or locations (single, ranked answers) were perceived as relevant. When ranking risk 
factors, a majority of HCP (73%) chose frequent intravenous or oral antibiotics (i.e., frequency < 
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every 2 months) over prolonged oral antibiotics (15%), >2 inpatient admissions per year (6%), 
and older age (6%).  Among PWCF/Parents the majority (57%) chose frequent antibiotics over 
prolonged oral antibiotics (21%), >2 inpatient admissions per year (12%), and older age (10%). 
Pseudomonas spp. (69%, 69%) and Burkholderia spp. (55%, 43%) were most concerning to HCP 
and PWCF/Parents, followed in frequency (52%) by non-tuberculosis mycobacteria (NTM) among 
HCP. Interestingly, HCP were less concerned than PWCF/Parents about Staphylococcus aureus 
in general (12% vs. 28%), but concerns for methicillin-resistant Staphylococcus aureus (MRSA) 
doubled in both groups (25% vs. 47%); MRSA infection is often highlighted in lay media and may 
lead to worse outcomes in PWCF.14,15  Other organisms and distributions by country/continent are 
shown in Table 2. 
Consequences of AMR 
Congruence was high between HCP and PWCF/Parents for perceived consequences of AMR, 
including the influence of AMR on the choice of antibiotics (89% of HCP and 81% of PWCF/ 
Parents agree) and AMR adversely affecting life expectancy (88% of HCP and 92% of PWCF 
agree). There was less congruence for “AMR affects response to antibiotics” (94% of HCP and 
78% of PWCF/Parents). We also asked whether “PWCF/Parents did not complete their antibiotic 
course as prescribed because of concerns of AMR”. Among HCP, 86% did not think this 
occurred, compared to 77% of PWCF/Parents who stated never having not completed therapy. 
Parents answered “never” in 83% of cases  compared to 75% of adults vs. 57% of  adolescents 
with CF. Additionally, 16% of PWCF/Parents stated they rarely had not completed therapy, 2% 
stated not completing therapy often, and 1% (n=3) responded “always”. 
Frequency and type of AMR education 
Results regarding the estimated frequency of information provided to PWCF/Parents showed a 
discrepancy between groups in response rate (HCP 89% vs. PWCF/F 73%, p<0.001), with 
equal distribution of missing answers within the sub-groups of PWCF/Parents.  The HCP 
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estimated providing AMR education to PWCF/Parents at a frequency of 38%, 45%, and 17% 
once a year, every other visit, or every visit, respectively. Among responding PWCF/Parents, 
only 50% stated that they were given information about AMR, yet this differed by subgroups with 
64% of adults and 63% of adolescents with CF compared to 39% of parents remembering this. 
Only 35% of PWCF/Parents provided an estimated frequency of AMR discussions, with once a 
year (61%), every other visit (32%) and at every clinic visit (7%) and those estimates were 
similar across PWCF/Parents subgroups.  
Fifty percent of HCP provided free text answers discussing the context in which they provided 
AMR education. The most common situations were related to antibiotic treatment or to hospital 
admissions (jointly 66%), 17% discussed AMR when new or newly resistant bacteria were 
isolated, 9% discussed AMR as part of routine education or when prompted by PWCF/Parents, 
and 8% had various/other responses. PWCF/Parents stated that the following information was 
included (>1 option): definition of AMR (61%), infection control measures (61%), and antibiotic 
overuse (38%).  
Responses about current resources PWCF/Parents utilized to obtain information on AMR were 
similar between the groups and showed that the preferred source of information was 
communication from their CF team (Figure 2). Open comments further suggested that flyers 
and handouts would be desired followed by national or international CF specific websites. 
Expectations and attitudes towards Antimicrobial Stewardship among HCP 
Response rate for the AMS questions was 86%. Available resources reported by respondents 
were pharmacists (69%), infectious disease consultation (65%), and local written exacerbation 
guidelines (55%). Fewer had a formal AMS program (39%), pre-approval process for restricted 
antibiotics (41%), and post-prescription feedback and audit (8%) in their institution. Most 
respondents perceived that choosing and dosing antibiotics appropriately and reducing AMR 
were the main goals of AMS (Figure 3). When asked whether they believed that AMS 
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programs preserved the activity of antibiotics, a higher proportion thought this to be true in 
people without CF (71%) vs. people with CF (55%). About a third stated that they didn’t know 
whether AMS was helpful in those without CF (26%) or those with CF (34%). The effect of 
AMS in managing CF exacerbations was considered to be “a large impact” by 32% of HCP and 
“to have some impact” by 58%.Ten percent thought AMS would have “minimal to no impact”. 
Stewardship activities considered useful during CF exacerbations included: choice of 
antibiotics (83%), duration of antibiotics (78%), dose of antibiotics (68%), therapeutic drug 
monitoring (63%), minimizing drug interactions (53%), and avoiding toxicity (50%). Nine 
percent of respondents stated that they did not know the benefit of AMS during exacerbations. 
DISCUSSION 
A survey of over 900 HCP and PCWF/Parents from over 30 countries illustrated that AMR was 
thought to be important to care and that responses between HCP and PWCF/Parents were 
largely congruent.  A majority of HCPs and PWCF/Parents were “very concerned” about AMR 
and listed frequent use of antibiotics as the most important risk factor. A high proportion of HCP 
and PWCF/Parents felt that AMR affected life expectancy. Concerns about person-to-person 
transmission of infection as a source for AMR was listed by over 50% of respondents 
(PWCF/Parents > HCP) (Table 1). This is an important finding as such concerns may affect the 
likelihood of PWCF attending appointments, which was mentioned in open text by some 
PWCF/Parents. This also stresses the need for ongoing focus on infection prevention, 
education, and control measures. Interestingly, most HCPs believed they discussed AMR with 
PWCF/Parents; however, fewer PWCF/Parents remembered receiving this information, 
especially parents. This highlights the need for HCP to provide better means of education, e.g. 
written handouts.  
A recent priority-setting exercise, involving both the lay and clinical CF communities, identified 
the negative effects of antibiotics (including development of antimicrobial resistance) as one of 
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This is consistent with answers given by PWCF in  surveys 
conducted through the U.S. CF Foundation, where PWCF listed respiratory microorganism 
detection and treatment as the top research priority.18,19
  
However, a central paradox of CF care is 
that, whilst antibiotic resistance is prevalent, there appears to be little relationship between the 




Such a paradox may be compounded by historical data from U.S. CF centers showing better 
pulmonary outcomes with higher intravenous antibiotic use;7,8,22 this was not seen in a more 
recent study using the UK CF Patient Registry.23  
This study has limitations. Given the self-selection of respondents, they may be more aware of 
AMR and AMS compared to other people in professional and lay communities. The English 
language survey may have limited response rate among non-native English speakers in Europe; 
however, this did not seem to affect results by those who took the survey. Additionally, surveys 
were subject to recall bias and responses were restricted to the questions asked on the survey.  
Although the survey included 27 and 23 questions for HCP and PWCF/Parents, respectively, the 
response rate did not decrease towards the later questions.  
Our findings imply that “road testing” of specific approaches to patient education about AMR 
(such as infographics and podcasts) and looking at the effectiveness of different media (social 
media vs. written material from the CF center) would be of particular interest. Both HCPs and 
PWCF/Parents would like to see research that evaluates antibiotic therapy to maximize 
effectiveness and avoid the emergence of resistance.
16,18,24  This may include measures to 
reduce the need for antibiotics, such as eradication strategies25,26 to prevent development of 
persistent infection, systematically evaluating the duration of antibiotics for exacerbations 
(STOP2 and Ped. STOP trial)27,28 and measures of infection prevention and control.29 There is a 
need to understand how microbiologic lab testing can best inform treatment decisions as current 






Other suggestions for AMS have recently been proposed, such as strengthening relationships 
between CF clinical and AMS teams, in order to consider implementing stewardship strategies.9 
The disconnect between antibiotic strategies and clinical outcomes suggest that both basic 
science and translational approaches are needed. As an immediate direction, HCP should 
enhance their discussions about AMR during CF clinic visits to educate a broader audience 
given that PWCF/Parents want to learn about AMR from their providers. 
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Figure 1: Characteristics of Respondents for A) Health care providers (HCP) showing country 
of current work and their role in CF care; B) People with CF (PWCF) with country. Fourteen 
did not provide a response regarding their role/connection to CF. Abbreviations: Inf Ctr = 




Figure 2: Sources where HCP perceive PWCF get information about antimicrobial resistance; 




Figure 3: Healthcare provider responses to questions on the goals of antimicrobial stewardship in 






Table 1: Perceived situational and location-specific risk factors by HCP and PWCF 
 
Situational risk % of 
respondents 
Location-specific risk % of 
respondents 
 HCP PWCF  HCP PWCF 
Cycled inhaled antibiotics 31.5 29.3 Home  3.0 1.7 
Country of residence 28.5 21.4 School or work  1.8 6.4 
Frequent inpatient 
antibiotics 
81.1 63.1 CF outpatient clinic 
appointment 
28.2 22.0 
Any hospitalization 31.9 40.5 Inpatient admissions 53.1 47.0 
Frequent outpatient 
antibiotics 
78.8 66.3 Non-CF medical appointment   7.2   9.0 
Same antibiotics within 3 
months 
54.9 48.4 Non-healthcare crowded 
areas 
   6.7 13.9 
Transmission among PWCF 51.4 56.6 Other / no response   <1   <1 
CFTR mutation 16.9 17.9    
Other   5.8   5.6    
 
Table 1: 397 healthcare providers (HCP) and 341 people with CF (PWCF) responded to the 
situational risk questions. Respondents were able to choose more than one answer for 
situational risks. Responses to the location-specific risk questions came from 401 HCP and 345 
















 % of respondents % of respondents % of respondents 
 HCP PWCF HCP PWCF HCP PWCF 
Pseudomonas 38 (66) 77 (65) 65 (53) 94 (48) 163 (68) 72 (55) 
Burkholderia 28 (48) 41 (35) 63 (52) 55 (28) 115 (48) 56 (42) 
Staphylococcus 5 (9) 30 (25) 11 (9) 38 (19) 32 (13) 30 (23) 
NTM 32 (55) 25 (21) 55 (45) 41 (2) 114 (48) 31 (23) 
MRSA 9 (16) 49 (42) 22 (18) 60 (31) 66 (28) 55 (42) 
Streptococcus 0 13 (11) 1 (1) 18 (9) 5 (2) 19 (14) 
Stenotrophomonas 3 (5) 8 (7) 12 (10) 10 (5) 31 (13) 7 (5) 
Aspergillus 1 (2) 23 (19) 6 (5) 23 (12) 18 (8) 24 (18) 
 
Influenza virus 0 12 (10) 1 (1) 5 (3) 3 (1) 12 (9) 
Table 2: Healthcare providers’ (HCP) and people with cystic fibrosis (PWCF) level of concern by 
organism for antimicrobial resistance (AMR) shown by continent. Percentage of respondents 
(%) by continent exceeds 100 as participants could choose up to two organisms. NTM – non-
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